IL23R and spondylitis: Interestingly, a study in the HLA-B27 transgenic rat model with arthritis and spondylitis showed that IL-23R inhibition is effective for disease prevention when given prior to clinical onset, but when used for treatment of established disease, anti-IL-23R did not reduce clinical features or levels of IL-17 and IL-22 (38).